Partner Headlines - THRX

  1. Richard Perry's Fourth-Quarter Transactions Had High Impact on ...

    GuruFocus
  2. Mylan Makes Deals In Women's Health, Lung Disease

    IBD
  3. Seth Klarman Keeps Buying LNG, KERX, PBF And Keeps Selling THRX

    GuruFocus
  4. Bank Of America Q3 Small & Mid-Cap Biotech Preview

    Benzinga
  5. Data Published on Anoro(R) Ellipta(R) Demonstrate Improved Lung ...

    GuruFocus
  6. Drug M&A Boom Driven By Long-Term Trends: PwC

    IBD
  7. Barron's Recap: Ready To Wear?

    Benzinga
  8. UPDATE: Bank Of America Downgrades Theravance As Pricing Headwinds ...

    Benzinga
  9. UPDATE: Morgan Stanley Reiterates On Theravance As Slow Trends ...

    Benzinga
  10. Theravance, Inc. Appoints Theodore J. Witek, Jr. As Senior VP, ...

    Benzinga
  11. UPDATE: Stifel Downgrades Theravance Following Post-Split Accretion

    Benzinga
  12. Benzinga's Top Downgrades

    Benzinga
  13. UPDATE: Glaxo, Theravance Report Positive Data from Two Studies ...

    Benzinga
  14. Theravance Announces Positive Results From a Phase 2 Study of ...

    Benzinga
  15. Theravance Announces Initiation of Phase 2b Study With TD-42 ...

    Benzinga
  16. Glaxo's COPD Drug Gets European Green Light

    FoxBusiness
  17. Morgan Stanley Expects Theravance to Continue to Underperform ...

    Benzinga
  18. Top 2013 Drug Approvals: Pharma Stocks

    YCharts
  19. Positive data for asthma drug

    IBD
  20. Theravance, Glaxo COPD Drug Does Well In Asthma

    IBD
  21. Seth Klarman Buys Micron Technology, Theravance, PBF Energy, ...

    GuruFocus
  22. GlaxoSmithKline

    IBD
  23. US Stock Futures Signal Flat Start On Wall Street

    Benzinga
  24. Relvar Ellipta Approved in Japan for Treatment of Asthma

    Benzinga
  25. Glaxo, Theravance Confirm Positive CHMP Opinion for Relvar Ellipta

    Benzinga
  26. Glaxo, Theravance Confirms FDA Panel Has Recommended Approval ...

    Benzinga
  27. Theravance Reports Results from Phase 2B Study 0091 with TD-42 ...

    Benzinga
  28. Missed Klarman’s 47% Gainer? His Other Value Pick

    YCharts
  29. Seth Klarman's Top 5 Second Quarter Holdings

    GuruFocus
  30. Perrigo-Elan Merger Creates Unlikely Pharma Union

    IBD
  31. UPDATE: Stifel Nicolaus Cuts PT to $37 on Theravance Ahead of ...

    Benzinga
  32. Theravance to Offer $250 Million Convertible Subordinated Notes ...

    Benzinga
  33. Weekly Guru Bargains Highlights: PANL, THRX, ZNGA, LORL, AMRN

    GuruFocus
  34. Theravance Confirms Favorable Ruling from FDA Panel on VIBATIV

    Benzinga
  35. Theravance Offers FDA Briefing Documents for Panel Meeting on ...

    Benzinga
  36. Theravance Enters Agreement With Alfa Wassermann Worth Up To ...

    Benzinga
  37. The Baupost Group's Favorite Stocks

    Benzinga
  38. Theravance Inc. (THRX) Sr VP, CFO Michael W Aguiar sells 24,682 ...

    GuruFocus
  39. GSK and Theravance Announce Completion of the Phase III Programme ...

    Benzinga
  40. Weekly CFO Sells Highlight: SWN, BECN, NSIT, HOLX, QLTI, THRX

    GuruFocus
  41. Theravance Inc. (THRX) Sr VP, CFO Michael W Aguiar sells 60, ...

    GuruFocus
  42. Theravance Inc. (THRX) CEO Rick E Winningham sells 75,749 Shares

    GuruFocus
  43. A Peek Into The Market Before The Trading Starts

    Benzinga
  44. GSK and Theravance Announce Regulatory Submissions for FF/VI ...

    Benzinga
  45. Target, Amgen Among Stocks Hitting 52-Week Highs Wednesday

    FoxBusiness
  46. Dendreon, Pharmacyclics and Other Biotech Takeover Targets

    Benzinga
  47. Merck &, Questcor Pharmaceuticals, Other Stocks Hit 52-Week Highs ...

    FoxBusiness
  48. Health Care Sector Wrap

    FoxBusiness
  49. Health Care Sector Wrap

    FoxBusiness
  50. GSK and Theravance Announce Positive Results From Four Pivotal ...

    Benzinga
  51. Theravance Inc. Reports Operating Results (10-K)

    GuruFocus
  52. UPDATE: Morgan Stanley Initiates Underweight, $12 PT on Theravance

    Benzinga
  53. Morgan Stanley Initiates Theravance at Underweight

    Benzinga
  54. Afternoon Movers; Markets Moved Higher

    Benzinga
  55. Morning Market Losers

    Benzinga
  56. From Earlier: GSK and Theravance Announce Initial Outcomes From ...

    Benzinga
  57. UPDATE: Piper Jaffray Raises Price Target on Theravance to $35

    Benzinga
  58. Piper Jaffray Raises PT on Theravance to $35

    Benzinga
  59. Notable Put Options Activity in Theravance

    Benzinga
  60. Theravance Inc. (THRX) Sr VP, CFO Michael W Aguiar sells 10, ...

    GuruFocus
Trading Center